CoChat

Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker

Open access
Simonian, Miganoosh, Mosallayi, Meysam, Mirzaei, Hamed · 2018 · Journal of Cancer Research and Therapeutics
Cited by 103

The DOI matches its Crossref record.

Abstract

Sir, Gastric cancer (GC) is known the second leading cause of cancer death worldwide. In 2012, it occurred in 950,000 people and led to 723,000 deaths. Despite many advances in treatment of GC, patients show poor prognosis and the 5-year survival rate is 5–20%.[1] Therefore, identifying novel biomarkers open new landscapes in diagnosis and prognosis for various stages of GC. Among of various biomarkers, microRNAs (miRNAs) have emerged as the potential diagnosis and prognosis biomarkers in GC therapy.[2] Several evidence revealed that they involve in pathogenesis pathways. Circulating miRNAs are present in cell-free body fluids such as serum, plasma, and urine. These molecules such as miR-21 can be utilized as the potential biomarkers in several malignancies such as GC and other digestive cancers. miR-21 upregulated in GC lead to inhibition of various tumor suppressor genes including PTEN, RECK, and PDCD4.[3] The suppression of these genes can promote proliferation, migration, and apoptosis inhibition. In addition, several studies demonstrated that upregulation of miR-21 is associated with poorer survival, worse tumor differentiation, lymph node metastasis, and tumor-node-metastasis stage.[4] Therefore, miR-21 detection has a prognostic value in patients with GC. Several studies showed that the diagnostic sensitivity and specificity of this biomarker is 78% and 89%, respectively, which are largely higher than other serum markers such as carcinoembryonic antigen and CA19-9 in clinics.[34] On the other hand, some reports showed low prognosis power and diagnosis accuracy for this molecule. Hence, increasing prognosis and diagnosis accuracy has been suggested the utilizing of various combination of miRNAs with miR-21 such as miR-27a and miR-106 that they also upregulated in plasma or serum of patient with GC.[45] Finally, miR-21 has a great potential to serve as new biomarkers in the treatment of GC. FINANCIAL SUPPORT AND SPONSORSHIP Nil. CONFLICTS OF INTEREST There are no conflicts of interest.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/0973-1482.175428

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 103

Metadata

Authors
Simonian, M., Mosallayi, M., & Mirzaei, H.
Venue
Journal of Cancer Research and Therapeutics
Publisher
Medknow
Published
2018
Volume
14
Issue
2
Pages
475
ISSN
0973-1482 (ISSN-L)
OpenAlex
W2800736042
Cited by
103
References
0
FWCI
5.22
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker. https://app.cochat.ai/papers/10.4103/0973-1482.175428
The paper
Simonian, M., Mosallayi, M., & Mirzaei, H. (2018). Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker. Journal of Cancer Research and Therapeutics. https://doi.org/10.4103/0973-1482.175428

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.